34970-21-3

Upstream product

• 34970-18-8 3,3-dimethylcyclobutanecarboxylic acid 

Downstream Products

• 90949-39-6 3,3-Dimethyl-cyclobutan-1-carbonsaeure-dimethylamid 
• 1192-33-2 3,3-dimethylcyclobutan-1-one 
• 19037-73-1 1,1-dimethyl-3-methylenecyclobutane 
• 52708-22-2 3,3-Dimethyl-1-vinylcyclobutan 
• 1393125-75-1 4-(3,3-dimethyl-cyclobutanecarbonyl)-benzoic acid ethyl ester 
• 1393126-14-1 ethyl 4-((3,3-dimethylcyclobutyl)(hydroxy)methyl)benzoate 
• 1393126-15-2 ethyl 3-(4-(3,3-dimethylcyclobutanecarbonyl)benzamido)propanoate 
• 1393126-16-3 4-(3,3-dimethylcyclobutanecarbonyl)benzoic acid 
• 1393126-17-4 ethyl 3-(4-((3,3-dimethylcyclobutyl)(hydroxy)methyl)benzamido)propanoate 
• 1393124-81-6 (+/-)-3-(4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzamido)propanoic acid 
• 1393127-56-4 ethyl 4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzoate 
• 1393127-57-5 4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzoic acid 
• 1421348-49-3 C₂₆H₂₈FN₃O₃ 
• 1421348-50-6 C₂₆H₂₈FN₃O₃ 

Relevant academic research and scientific papers

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

QUINOLINYL GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.